The present disclosure, relates, in general, to hydrophobic salts of hydrophilic peptides that form low solubility materials in aqueous solutions and are capable of extended or sustained release of the peptide component when administered to a subject. Hydrophobic salts of C-type natriuretic peptides and uses thereof are also disclosed.

The present disclosure, relates, in general, to hydrophobic salts of hydrophilic peptides that form low solubility materials in aqueous solutions and are capable of extended or sustained release of the peptide component when administered to a subject. Hydrophobic salts of C-type natriuretic peptides and uses thereof are also disclosed.

The present disclosure relates to highly dispersible zinc phthalocyanine-silica nanotubes and a preparation method thereof. More particularly, the present disclosure relates to highly dispersible zinc phthalocyanine-silica nanotubes capable of improving the dispersibility of zinc phthalocyanine so that the zinc phthalocyanine can be easily absorbed in the body, and to a method of preparing highly dispersible zinc phthalocyanine nanotubes. The present disclosure proposes a highly dispersible zinc phthalocyanine-silica nanotube and a method of preparing sample. The method includes a first step of mixing a template with a alcohol solution to prepare a nanotube solution containing a nanotube template, a second step of adding a zinc phthalocyanine (ZnPc) solution to the nanotube solution and stirring the resulting mixture to prepare a zinc phthalocyanine-silica nanotube solution, a third step of adding a silica precursor to the zinc phthalocyanine-nanotube solution and stirring the resulting mixture to induce silication, thereby preparing a zinc phthalocyanine-silica nanotube solution, and a fourth step of filtering and drying the zinc phthalocyanine-silica nanotube to prepare zinc phthalocyanine nanotube powder. Further proposed is a method of preparing the zinc phthalocyanine powder.

The present disclosure relates to highly dispersible zinc phthalocyanine-silica nanotubes and a preparation method thereof. More particularly, the present disclosure relates to highly dispersible zinc phthalocyanine-silica nanotubes capable of improving the dispersibility of zinc phthalocyanine so that the zinc phthalocyanine can be easily absorbed in the body, and to a method of preparing highly dispersible zinc phthalocyanine nanotubes. The present disclosure proposes a highly dispersible zinc phthalocyanine-silica nanotube and a method of preparing sample. The method includes a first step of mixing a template with a alcohol solution to prepare a nanotube solution containing a nanotube template, a second step of adding a zinc phthalocyanine (ZnPc) solution to the nanotube solution and stirring the resulting mixture to prepare a zinc phthalocyanine-silica nanotube solution, a third step of adding a silica precursor to the zinc phthalocyanine-nanotube solution and stirring the resulting mixture to induce silication, thereby preparing a zinc phthalocyanine-silica nanotube solution, and a fourth step of filtering and drying the zinc phthalocyanine-silica nanotube to prepare zinc phthalocyanine nanotube powder. Further proposed is a method of preparing the zinc phthalocyanine powder.

Provided herein are apohemoglobin-haptoglobin complexes as well as apohemoglobin-haptoglobin complexes comprising an active agent coordinated thereto. Methods of using these compositions are also described.

Provided herein are apohemoglobin-haptoglobin complexes as well as apohemoglobin-haptoglobin complexes comprising an active agent coordinated thereto. Methods of using these compositions are also described.

Disclosed herein are compositions comprising one or more therapeutic proteins for oral administration. The disclosed proteins, which may be directed to a variety of GI and systemic target antigens, resist denaturation and degradation in the stomach and intestines of a patient. The disclosed proteins may be delivered intact to a target region within the gut, or anywhere in body to target specific molecules, cells, tissues, or organs. In some embodiments, the disclosed proteins may include two or more proteins for targeting two or more target antigens.

Disclosed herein are compositions comprising one or more therapeutic proteins for oral administration. The disclosed proteins, which may be directed to a variety of GI and systemic target antigens, resist denaturation and degradation in the stomach and intestines of a patient. The disclosed proteins may be delivered intact to a target region within the gut, or anywhere in body to target specific molecules, cells, tissues, or organs. In some embodiments, the disclosed proteins may include two or more proteins for targeting two or more target antigens.

Provided is a nanogel exhibiting anticoagulation and antioxidation activities, including a graphene-like nanosheet and a polysaccharide, which are complexed to form a cross-linked supramolecular structure. Also provided is a method of preparing the nanogel, including carbonizing the polysaccharide by dry heating. By the heating process, at least a portion of the polysaccharide is conversed into the graphene-like nanosheet, thereby forming a graphene-like nanosheet-embedded phenolic-polysaccharide nanogel that has exceptional polyphenolic structure and high binding affinity toward thrombin. Further provided is a method of preventing or treating a disease or a condition susceptible to amelioration by anticoagulants or antioxidants by using the nanogel.

Provided is a nanogel exhibiting anticoagulation and antioxidation activities, including a graphene-like nanosheet and a polysaccharide, which are complexed to form a cross-linked supramolecular structure. Also provided is a method of preparing the nanogel, including carbonizing the polysaccharide by dry heating. By the heating process, at least a portion of the polysaccharide is conversed into the graphene-like nanosheet, thereby forming a graphene-like nanosheet-embedded phenolic-polysaccharide nanogel that has exceptional polyphenolic structure and high binding affinity toward thrombin. Further provided is a method of preventing or treating a disease or a condition susceptible to amelioration by anticoagulants or antioxidants by using the nanogel.